Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride provides potassium ions for cellular electrochemical activity; dextrose is a caloric agent that increases blood glucose levels; sodium chloride is an electrolyte replenisher that maintains osmotic balance and fluid distribution.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Continuous IV infusion at a rate of 0.5-1 L/hr, providing potassium 10-20 mEq/hr, dextrose 10 g/hr, and sodium chloride 154 mEq/L; administer via central or peripheral line as a maintenance or replacement solution. Adjust rate based on serum potassium, glucose, and sodium levels and clinical status.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
No defined half-life for the combined product; potassium has an elimination half-life of approximately 2–3 hours in healthy individuals, though it is highly dependent on renal function and body stores. Dextrose and sodium chloride are rapidly distributed and eliminated with half-lives of 15–30 minutes and 2–4 hours, respectively.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium is primarily excreted renally (>90%) via glomerular filtration and distal tubular secretion; a small fraction (approximately 10%) is lost via feces, with minimal biliary excretion. Sodium and chloride are likewise predominantly eliminated in urine (>95%). Dextrose is metabolized to CO2 and water.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."